Literature DB >> 27616624

Interleukin 35: A novel candidate biomarker to diagnose early onset sepsis in neonates.

Wei-Xia Du1, Yu He2, Hong-Yan Jiang1, Qing Ai2, Jia-Lin Yu3.   

Abstract

BACKGROUND: Early onset sepsis (EOS) remains a major cause of morbidity and mortality in newborns; however, current diagnostic tools are inadequate. We evaluated the accuracy of a novel cytokine, interleukin (IL)-35, for the diagnosis of EOS in comparison with other infection markers.
METHODS: One hundred fifty-seven neonates with suspected sepsis in the first 3days of life were enrolled in this perspective study. All enrolled patients were divided into infected group and unlikely infected group according to clinical data. IL-35, C-reactive protein (CRP), procalcitonin (PCT), white blood cell (WBC) count, and blood culture were measured once the suspected EOS was documented.
RESULTS: Serum concentration of IL-35 was increased significantly in the infected group compared with the unlikely infected group (median 36.4 versus 27.1pg/ml, respectively, p<0.001). The area under receiver-operating characteristic (ROC) curve were 0.756 for IL-35, 0.713 for PCT (age-adjusted), 0.670 for CRP, and 0.619 for WBC. With a cut-off value of 31.7pg/ml, the diagnostic sensitivity and specificity of IL-35 were 78.48% and 66.67%, respectively. Moreover, unlike PCT concentration, IL-35 concentration did not fluctuate in neonates who were unlikely to be infected (p=0.885).
CONCLUSION: The diagnostic performance of IL-35 was superior to that of PCT and other commonly used markers, suggesting that IL-35 may be a valuable tool for EOS diagnosis.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Biomarker; Early onset sepsis; Interleukin 35; Neonate

Mesh:

Substances:

Year:  2016        PMID: 27616624     DOI: 10.1016/j.cca.2016.09.005

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  IL-35, as a newly proposed homeostasis-associated molecular pattern, plays three major functions including anti-inflammatory initiator, effector, and blocker in cardiovascular diseases.

Authors:  Xinyuan Li; Pu Fang; William Y Yang; Hong Wang; Xiaofeng Yang
Journal:  Cytokine       Date:  2017-06-23       Impact factor: 3.861

2.  IL35 attenuated LPS-induced acute lung injury by regulating macrophage polarization.

Authors:  Shengsong Chen; Jingen Xia; Yi Zhang; Qingyuan Zhan
Journal:  Mol Biol Rep       Date:  2022-06-24       Impact factor: 2.742

Review 3.  The Role, Involvement and Function(s) of Interleukin-35 and Interleukin-37 in Disease Pathogenesis.

Authors:  Ramatu Omenesa Bello; Voon Kin Chin; Mohammad Faruq Abd Rachman Isnadi; Roslaini Abd Majid; Maizaton Atmadini Abdullah; Tze Yan Lee; Zainul Amiruddin Zakaria; Mohd Khairi Hussain; Rusliza Basir
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923

4.  IL-18 and IL-35 in the serum of patients with sepsis thrombocytopenia and the clinical significance.

Authors:  Meirong Zhu; Xiaoqian Rong; Min Li; Shaoqin Wang
Journal:  Exp Ther Med       Date:  2019-12-18       Impact factor: 2.447

5.  Elevated levels of interleukin-35 and interleukin-37 in adult patients with obstructive sleep apnea.

Authors:  Bi Chen; Ya-Nan Liu; Lei Ji; Ping-Li Liu; Jun He; Yu-Ying Gan; Gui-Juan Ji; Shu-Yang Zhu; Wen-Hui Zhang
Journal:  J Clin Lab Anal       Date:  2021-05-04       Impact factor: 2.352

6.  G-CSF as a potential early biomarker for diagnosis of bloodstream infection.

Authors:  Huimin Li; Zhen Wang; Xuehua Li
Journal:  J Clin Lab Anal       Date:  2021-11-01       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.